"Since ~90% of the patients in BETonMACE have normal kidney function (median 99, mean above 100), the total population eGFR data is dominated by these patients and in my opinion masks/hides the 10% of patients w/ baseline eGFR<60 that we want to see."
Bear seeing that this applies to both sides ( treated v placebo), the data gathered from the 10% still tells a good story for ABL.
Koo